 As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies. Featured Image for Gb Sciences Featured Image for Gb Sciences LAS VEGAS, Dec. 12, 2022 GLOBE NEWSWIRE Gb Sciences, Inc. OTCQB:GBLX, a leading plant-inspired, biopharmaceutical research ... The post Gb Sciences Addresses Growing Need for Anxiety and Depression M... 